Speaker List - 2018 Archive

2018 Archived Content

OVERVIEW | DOWNLOAD BROCHURE | SPEAKERS | SHORT COURSES | TRAINING SEMINARS

PLENARY KEYNOTES

K. Dane Wittrup, PhD, C.P. Dubbs Professor, Chemical Engineering and Biological Engineering; Associate Director, Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology (MIT)
2018 YOUNG SCIENTIST KEYNOTE
Kipp Weiskopf, MD, PhD, Resident Physician, Internal Medicine, Brigham and Women’s Hospital

Engineering Stream
DISPLAY OF ANTIBODIES

Andrew M. Bradbury, PhD, MB BS, CSO, Specifica, Inc.
Frederic D. Bushman, PhD, Chair and Professor, Microbiology, University of Pennsylvania
Bryce Chackerian, PhD, Professor, Molecular Genetics and Microbiology, University of New Mexico School of Medicine
Ross Chambers, PhD, Vice President, Antibody Discovery, Integral Molecular
Stefan Ewert, PhD, Senior Investigator, NIBR Biologics Center, Novartis Pharma AG
Benjamin Hackel, PhD, Associate Professor, Chemical Engineering and Materials Science, University of Minnesota
Guy Hermans, PhD, CSO, Isogenica Ltd.
Mitchell Ho, PhD, Senior Investigator, National Cancer Institute, NIH
Joseph Jardine, PhD, Head, Antibody Discovery, Institute for Protein Innovation
David R. Liu, PhD, Richard Merkin Professor, Director, Merkin Institute of Transformative Technologies in Healthcare, Broad Institute Core Institute Member, Vice-Chair, Faculty, Director of the Chemical Biology and Therapeutic Sciences Program, Howard Hughes Medical Institute Investigator, Professor, Chemistry and Chemical Biology, Harvard University
Chuanbin Mao, PhD, Professor, Chemistry and Biochemistry, University of Oklahoma
Jennifer Maynard, PhD, Associate Professor, Chemical Engineering, University of Texas at Austin
Vera Molkenthin, PhD, Chief Scientist, AbCheck s.r.o.
James M. Olson, MD, PhD, Sarah Hughes Chair for Pediatric Oncology; Member, Fred Hutchinson Cancer Research Center; Attending Physician, Seattle Children’s Hospital; Professor of Pediatrics, University of Washington
Timothy Palzkill, PhD, Professor, Chair, Pharmacology and Chemical Biology, Baylor College of Medicine
Balaji M. Rao, PhD, Associate Professor, Chemical and Biomolecular Engineering, North Carolina State University
Aaron Sato, PhD, CSO, Antibody Center, LakePharma
Leila Sevigny, PhD, Senior Scientist, Sanofi Genzyme
Ernest Smith, CSO & Senior Vice President, Research, Vaccinex, Inc.
Greg M. Thurber, PhD, Assistant Professor, Chemical Engineering and Biomedical Engineering, University of Michigan
Benjamin Umlauf, PhD, Post-Doctoral Fellow, Chemical and Biological Engineering Department, University of Wisconsin

ENGEINEERING ANTIBODIES

Joel Cohen-Solal, PhD, Senior Research Scientist, Global Protein Sciences, AbbVie Bioresearch Center
Caroline Colley, PhD, Associate Director, Antibody Discovery and Protein Engineering, MedImmune, United Kingdom
Bruno Correia, PhD, Professor, Protein Design and Immunoengineering, EPFL Zurich, Switzerland
Abhishek Datta, Ph.D., Director, Antibody Discovery and Engineering, Scholar Rock
David S. Johnson, PhD, CEO, GigaGen
JT Koerber, PhD, Scientist, Antibody Engineering, Genentech
Tim Larson, PhD, Marketing Specialist I, Marketing, Takara Bio USA
Valerie Le Fourn, PhD, Research & Development Cell Culture Director, Selexis SA
Chang-Han Lee, PhD, Postdoctoral Researcher, Georgiou Lab, The University of Texas at Austin
Greg Lazar, PhD, Director, Antibody Engineering, Genentech
Jonas V. Schaefer, PhD, Lab Head/Investigator II, Novartis Institutes for BioMedical Research (NIBR)
Eva-Maria Strauch, PhD, Research Assistant Professor, Biochemistry, University of Washington
E. Sally Ward, Ph.D., Professor, Molecular and Cellular Medicine, Texas A&M Health Science Center
Danlin Yang, PhD, Scientist, Biotherapeutics Discovery, Boehringer Ingelheim
Andy Yeung, PhD, Associate Research Fellow, Rinat, Oncology R&D, Pfizer, Inc.

ENGINEERING BISPECIFIC ANTIBODIES

Edward A. Berger, PhD, Chief, Molecular Structure Section, Laboratory of Viral Diseases, NIAID, National Institutes of Health
Stanislas Blein, PhD, Senior Director, Head Antibody Engineering, Biologics Research, Glenmark Pharmaceuticals S.A.
Ulrich Brinkmann, PhD, Roche Pharma Research & Early Development, Large Molecule Research, Roche Innovation Center Munich (RICM), Penzberg, Germany
Yvonne Y. Chen, PhD, Assistant Professor, Chemical and Biomolecular Engineering, University of California, Los Angeles
Mark Cobbold, MD, PhD, Cellular Immunotherapy Program, Center for Cancer Immunology, Massachusetts General Hospital; Member of the Faculty of Medicine, Harvard Medical School
John de Kruif, PhD, CTO, Merus NV
Nicolas Fischer, PhD, Head of Research, Novimmune
Yanwen Fu, PhD, Director, Antibody Technology and Chemical Biology, Sorrento Therapeutics
Stephen Gottschalk, MD, Chair, Bone Marrow Transplantation & Cellular Therapy, St. Jude Children’s Research Hospital
Steven M. Larson, MD, FACNM, FACR, Donna and Benjamin M. Rosen Chair, Attending Molecular Imaging and Therapy Service, Radiology; Member and Lab Head, Molecular Pharmacology and Chemistry Program, Sloan Kettering Institute; Professor, Radiology, Weill Cornell University Medical Center, Radioimmunotherapy and Theranostics, Ludwig Center
Jeffrey S. Miller, MD, Professor of Medicine, Deputy Director, Masonic Cancer Center, Hematology, Oncology and Transplantation, University of Minnesota
Amarendra Pegu, PhD, Staff Scientist, Laboratory of Virology, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, NIH
Mitsuo Umetsu, PhD, Professor, Biomolecular Engineering, Graduate School of Engineering, Tohoku University
Thomas J. Van Blarcom, PhD, Associate Research Fellow, Oncology Research and Development, Pfizer, Inc., Rinat Laboratories
Maria Wendt, PhD, Head, Science, Biologics, Genedata
Chengbin Wu, PhD, CEO, EpimAb Biotherapeutics

Oncology Stream
ANTIBODIES FOR CANCER THERAPY

Ezio Bonvini, MD, Senior Vice President, Research & CSO, MacroGenics, Inc.
Paul B. Chapman, MD, Physician & Scientist, Memorial Sloan Kettering Cancer Center
Nai-Kong V. Cheung, MD, PhD, Head, Neuroblastoma Program; Enid A. Haupt Endowed Chair, Pediatric Oncology, Memorial Sloan Kettering Cancer Center
Bradley St. Croix, PhD, Senior Associate Scientist, Head, Tumor Angiogenesis Unit, Mouse Cancer Genetics Program, National Cancer Institute
Achim Doerner, PhD, Principal Scientist, Protein Engineering and Antibody Technologies, Merck KGaA Darmstadt, Germany
Gianpietro Dotti, MD, Lineberger Comprehensive Cancer Center Member, Professor, Microbiology and Immunology; Director, Lineberger Immunotherapy Program, University of North Carolina School of Medicine
Tim F. Greten, MD, Senior Investigator, GI Maligancy Section, Thoracic and GI Oncology Branch, Center for Cancer Research, National Cancer Institute
Frank Grosveld, PhD, Professor, Cell Biology, Erasmus MC; Founder, Harbour Antibodies BV, Harbour BioMed
Mitchell Ho, PhD, Senior Investigator, National Cancer Institute, NIH
Patrick Mehlen, PhD, CEO Netris Pharma, Centre Léon Bérard
Horacio G. Nastri, PhD, Senior Director, Antibody Biotherapeutics, Incyte Corporation
Junichi Nezu, PhD, Senior Specialist, Project & Lifecycle Management Unit, Chugai Pharmaceutical, Co., Ltd.
Patrick Ott, MD, PhD, Clinical Director, Melanoma Center; Clinical Director, Center for Immuno-Oncology, Dana-Farber Cancer Institute; Assistant Professor of Medicine, Harvard Medical School
Ira H. Pastan, MD, Scientist, NIH NCI
Soldano Ferrone, MD, PhD, Surgical Oncology, Surgery, Massachusetts General Hospital
Kelli Ryan, PhD, Senior Scientist, Oncology Department, MedImmune
William R. Strohl, PhD, Owner and President, BiStro Biotech Consulting, LLC
Mark Throsby, PhD, CSO, Merus NV
Jennifer Wargo, MD, Melanoma Research, MD Anderson Cancer Center
Louis Weiner, MD, Professor, Oncology and Lombardi Comprehensive Cancer Center, Georgetown University Medical Center
Mingjie Xie, CEO, Rapid Novor, Inc.

ADVANCING BISPECIFIC ANTIBODIES AND COMBINATION THERAPY TO THE CLINIC

Julian Andreev, PhD, Senior Staff Scientist, Oncology and Angiogenesis, Regeneron Pharmaceuticals
Tara Arvedson, PhD, Director, Oncology Research, Amgen, Inc.
Carl Uli Bialucha, PhD, Oncology Biotherapeutics, Novartis Institutes for BioMedical Research, Inc.
Adrian Bot, MD, PhD, CSO, Kite Pharma, Inc.
Chien-Hsing Ken Chang, PhD, Vice President, Research & Development, Immunomedics, Inc.
Raphael Clynes, MD, PhD, Vice President, Translational Biology, Xencor, Inc.
Frank Comer, PhD, Scientist, MedImmune
Rakesh Dixit, PhD, DABT, Vice President, R&D, Global Head, Biologics Safety Assessment, Translational Sciences, MedImmune
David D. Ho, MD, Aaron Diamond AIDS Research Center, The Rockefeller University
Dirk Hose, PhD, Priv.-Doz. Dr. med. Dr. biol. hom., Head, Multiple Myeloma Research Laboratory, Universitaetsklinikum Heidelberg, Medizinische Klinik V
Ross La Motte-Mohs, PhD, Scientist III, Cell Biology and Immunology, MacroGenics, Inc.
Mark Paris, PhD, Associate Director, Translational Applications, Mitra Biotech
G. Jonah Rainey, PhD, Executive Director, Head of Antibody Research, MabVax Therapeutics Holdings, Inc.
Volker Schellenberger, CEO & President, Discovery, Amunix
Leonard Seymour, PhD, Professor, Gene Therapy, Oncology, University of Oxford
Jacintha Shenton, PhD, Scientific Director, Biologics Toxicology, Janssen BioTherapeutics, Janssen R&D
Michael Tesar, PhD, Research Program Head, Research and Development, Affimed GmbH
Bob Valamehr, PhD, Vice President, Cancer Immunotherapy, Fate Therapeutics
Zhulun Wang, PhD, Executive Director, Biologics Department, Amgen

CLINICAL PROGRESS OF ANTIBODY-DRUG CONJUGATES

Adnan Abu-Yousif, PhD, Senior Scientist II, Discovery, Takeda
Donald A. Bergstrom, MD, PhD, CMO, Mersana Therapeutics
Anna Berkenblit, MD, MMSc, Vice President, CMO, ImmunoGen
Mahendra Deonarain, PhD, CEO & CSO, Antikor Biopharma Ltd.
David Goldenberg, ScD, MD, Founder and Former CSO, Immunomedics, Inc.
Trevor J. Hallam, PhD, CSO, Sutro Biopharma
Jay Harper, PhD, Senior Scientist, Oncology Research, MedImmune
Philip Howard, PhD, CSO, Spirogen; Senior Fellow, MedImmune
Gail Lewis Phillips, MSc, Senior Scientist, Translational Oncology, Genentech, Inc.
David (Shih-Yao) Lin, MD, PhD, CMO, AbGenomics, Inc.
Ed Reilly, PhD, Senior Research Fellow, Project Director, Oncology Discovery, AbbVie
Renu Singh Dhanikula, PhD, Senior Research Investigator, MAP, Bristol-Myers Squibb Company
Pamela Trail, Independent Consultant and Former Vice President, Oncology, Regeneron
Alessandra Micaela Villa, PhD, Head, Phage Display Technologies, Philochem AG
Jeff Wallin, PhD, Senior Director and Head, Biomarkers & Diagnostics, Seattle Genetics
William C. Zamboni, PharmD, PhD, Associate Professor and Director, Translational Oncology and Nanoparticle Drug Development Initiative (TOND2I) Laboratory, UNC Lineberger Comprehensive Cancer Center

Immunotherapy Stream
IMPROVING IMMUNOTHERAPY EFFICACY AND SAFETY

Andrew Allen, MD, PhD, President & CEO, Gritstone Oncology, Inc.
Carlo Boutton, PhD, Director Technology & Information Management, Ablynx
Daniel Christ, PhD, Associate Professor, Director Centre for Targeted Therapy, Garvan Institute of Medical Research
Robert Hofmeister, PhD, CSO, Executive Leadership Team, TCR2 Therapeutics, Inc.
Alex Kelly, US Business Development Manager, Retrogenix
Saad J. Kenderian, Assistant Professor of Medicine and Oncology, Mayo Clinic College of Medicine
Kathleen McGinness, PhD, Senior Director, Platform Technologies, Unum Therapeutics
Douglas Jolly, PhD, Executive Vice President, Research & Pharmaceutical Development, Research & Pharmaceutical Development, Tocagen Inc.
Maksim Mamonkin, PhD, Instructor, Center for Cell and Gene Therapy, Baylor College of Medicine
Daniel J. Powell Jr., PhD, Associate Professor of Pathology and Laboratory Medicine, University of Pennsylvania
Laszlo Radvanyi, PhD, Senior Vice President, Senior Scientific Advisor – Immunology, Immuno-Oncology, EMD Serono R&D Institute
Robert R. Salzler, PhD, Scientist, Bioanalytical & Biomarker Technologies, Regeneron Pharmaceuticals, Inc.
Steven Shamah, PhD, SVP, Head of Research, Obsidian
Naomi De Silva, PhD, Associate Director, Preclinical and Translational Science, Clinical, Sillajen Biotherapeutics, Inc.
Steven J. Swanson, PhD, Senior Vice President, Research, ImmunoCellular Therapeutics, Ltd.
Carston R. Wagner, PhD, Professor, Department of Medicinal Chemistry, University of Minnesota, and CSO, Tychon Bioscience, LLC
Claudia Wagner, PhD, Associate Director, TCR Discovery & Validation, Immatics

CAR Ts, TCRs AND TILs

J. Henri Bayle, PhD, Director of Molecular Biology, Research and Development, Bellicum Pharmaceuticals
Mark Bonyhadi, PhD, Head, Research, Juno Therapeutics
Adrian Bot, MD, PhD., Vice President, Translational Sciences, Kite, a Gilead Company
Mark Dudley, PhD, Senior Vice President, Bioprocessing & Development CMC, Technical Operations, Adaptimmune
Maria Fardis, PhD, CEO, Iovance
David Gilham, PhD, Vice President, Research, Celyad
Collin Hauskins, Research Scientist, Protein Sciences, Juno Therapeutics
Hans Klingemann, MD, PhD, Vice President, Research & Development, NantKwest, Inc.
Jeffrey S. Miller, MD, Professor of Medicine, Deputy Director, Masonic Cancer Center, Division of Hematology, Oncology and Transplantation, University of Minnesota University of Minnesota
Molly Perkins, DPhil, Associate Director, Immunotherapy, bluebird bio
Paul Rennert, PhD, President & CSO, Aleta Biotherapeutics Inc
Michel Sadelain, PhD, Director, Center for Cell Engineering, Memorial Sloan Kettering Cancer Center
Andrew Sewell, PhD, Professor, Division of Infection and Immunity, Cardiff University School of Medicine
Bob Valamehr, PhD, Vice President, Cancer Immunotherapy, Fate Therapeutics

AGONIST IMMUNOTHERAPY TARGETS

Adam J. Adler, PhD, Professor, Immunology, University of Connecticut
Casey Ager, Graduate Research Assistant, Department of Immunology, University of Texas MD Anderson Cancer Center
Saso Cemerski, PhD, Principal Scientist, Merck Research Labs
Deborah H. Charych, PhD, Executive Director, Nektar Therapeutics
Adi Diab, PhD, Assistant Professor, Department of Melanoma Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston
Peter Ellmark, PhD, Principal Scientist, R&D, Alligator Bioscience
Denise L. Faustman, MD, PhD, Director of Immunobiology, Massachusetts General Hospital, Associate Professor of Medicine, Harvard Medical School
Claudia Ferrara, PhD, Principal Scientist, Large Molecule Research, Roche Pharmaceutical Research and Early Development, Roche Innovation Center Zurich
Oliver Hill, PhD, Vice President, Molecular Biology, Apogenix
Debbie Law, DPhil, CSO, Jounce Therapeutics
Patrick Mayes, PhD, Executive Director, Head, IO Antibody Research, Incyte
Dafne Müller, PhD., Group Leader, Institute of Cell Biology and Immunology, University of Stuttgart
Taylor Schreiber, PhD, CSO, Research & Development, Shattuck Labs, Inc.
Harpreet Singh, President & CEO, Immatics US
Robert B. Stein, MD, PhD, Senior Advisor, R&D, Agenus, Inc.
Michael Yellin, MD, Vice President, Clinical Science, Celldex

Expression Stream
DIFFICULT TO EXPRESS PROTEINS

Bhupal Ban, PhD, Research Asst. Professor, Antibody Engineering & Technology, University of Virginia
Randal Bass, PhD, Vice President, Just Biotech
Matthew A. Coleman, PhD, Senior Scientist, Lawrence Livermore National Laboratory
Hussain Dahodwala, PhD, Post Doctoral Researcher, University of Delaware, Delaware Biotechnology Institute
Martin Gamer, PhD, Early Stage Bioprocess Development, Boehringer Ingelheim Pharma GmbH & Co. KG
Haruki Hasegawa, PhD, Department of Therapeutic Discovery, Amgen
Akinori Hishiya, PhD, Principal Scientist, Biology, SOLA BioSciences
David Laidlaw, CEO, Kuhner Shaker, Inc.
Kerstin Otte, PhD, Professor, Pharmaceutical Biotechnology, Biberach University
Harunur Rashid, PhD, Principal Scientist, Ambrx, Inc.
Fabio Cupri Rinaldi, PhD, Research Associate, Martin Lab, Cornell Univeristy
Paul Roepe, PhD, Professor, Chemistry, Biochemistry and Mol. Biology, Georgetown University
Gargi Roy, MSc, Scientist I, Antibody Discovery and Protein Engineering/Research, MedImmune LLC
Joop van den Heuvel, PhD, Department of Structure and Function of Proteins, Helmholtz Centre for Infection Research
Ernst Weber, PhD, Senior Scientist, Antibody Lead Discovery, Biologics Research, Bayer AG
Yi Xia, MD, Senior Scientific Researcher, Antibody Engineering, Genentech, Inc.
Alexei Yeliseev, PhD, Staff Scientist, Group Leader, LMBB, NIH, NIAAA

OPTIMIZING PROTEIN EXPRESSION

Nicola Beaucamp, PhD, Head, Process Research, Roche Innovation Center Munich, Pharma Research and Early Development, Roche Diagnostics GmbH
Imre Berger, PhD, Professor and Wellcome Trust Senior Investigator, Biochemistry, Biomedical Sciences and BrisSynBio Centre, University of Bristol
Colin Clarke, PhD, Principal Investigator, National Institute for Bioprocessing Research and Training (NIBRT)
Jan-Willem de Gier, PhD, Professor, Biochemistry and Biophysics, Stockholm University
Samuel Ellis, Vice President, Thomson Instrument Company
William Gillette, PhD, Principal Scientist, Deputy Director, Protein Expression Laboratory, Leidos Biomedical Research, Inc.
David Humphreys, PhD, Director and Head, Protein Sciences, UCB Pharma
Jesse Rinehart, PhD, Associate Professor, Cellular & Molecular Physiology, Systems Biology Institute, Yale University School of Medicine
Robert Roth, PhD, Associate Principal Scientist, Innovative Medicines, Discovery Sciences, AstraZeneca
Jorg Thommes, PhD, Senior Vice President, Pharmaceutical Sciences & Technology, Visterra, Inc.
Joop van den Heuvel, PhD, Research Group Leader, Recombinant Protein Expression, Helmholtz Centre for Infection Research
Bernd Voedisch, PhD, Lab Head and Investigator III, NIBR Biologics Center, Novartis Institutes for Biomedical Research
Bingyuan Wu, PhD, Senior Research Scientist, Janssen Pharmaceutical Companies of Johnson and Johnson
Jamey Young, PhD, Associate Professor, Chemical and Biomolecular Engineering, Vanderbilt University

PROTEIN EXPRESSION SYSTEM ENGINEERING

Abhishek Chatterjee, PhD, Assistant Professor, Chemistry, Boston College
Patricia L. Clark, PhD, Rev. John Cardinal O’Hara C.S.C. Professor, Biochemistry, University of Notre Dame
Michael Dyson, PhD, CTO, Antibody Engineering, IONTAS, Ltd.
Tobias Grosskopf, PhD, Scientist, Cell Culture Research, Roche Diagnostics GmbH
Olivier Henry, PhD, Associate Professor, Chemical Engineering, École Polytechnique de Montréal
Michael Jewett, PhD, Charles Deering McCormick Professor of Teaching Excellence, and Associate Professor, Chemical and Biological Engineering, Northwestern University
Eric Kelsic, PhD, Staff Scientist, Wyss Institute, Harvard University
Minseung Kim, MSc, Scientist, Computer Science, UC Davis Genome Center, University of California, Davis
Nathan Lewis, Systems Biology & Cell Engineering, University of California, San Diego
Colton Lloyd, PhD Candidate, Bioengineering, University of California, San Diego
Shahram Misaghi, PhD, Senior Scientist, Early Stage Cell Culture, Genentech, Inc.
Dimitris Papamichail, PhD, Assistant Professor, Computer Science, The College of New Jersey
Lisa Alexandra Pieper, PhD, Postdoctoral Researcher, Early Stage Bioprocess Development, Boehringer Ingelheim Pharma GmbH & Co. KG
Anokha S. Ratnayake, PhD, Principal Scientist, Pfizer Global R&D Groton Labs
Lars Stöckl, PhD, Senior Director, R&D, Glycotope GmbH

Analytical Stream
CHARACTERIZATION OF BIOTHERAPEUTICS

Michael Adamo, Senior Scientist, Bristol-Myers Squibb
Eric S. Alonzo, PhD, Scientist, Cellular Analytics, bluebird bio
Nathan Brown, PhD, Senior Scientist, AbbVie Bioresearch Center
Shan Chung, PhD, Principal Scientist and Group Leader, Genentech
Zhimei Du, PhD, Senior Principal Scientist, Merck & Company, Inc.
Mei Han, PhD, Senior Scientist, Pharmacokinetics & Drug Metabolism, Amgen, Inc.
Stacey Helming, PhD, Scientist, Analytical Sciences, Regeneron Pharmaceuticals
Vibha Jawa, PhD, Director, Biologics and Vaccine Development, Merck
Xin Jiang, Product Manager, iCE, Marketing, ProteinSimple, a Bio-Techne brand
Jay Jones, Senior Research Associate, Seattle Genetics
Lynn Kamen, PhD, Scientist, Bioanalytical Sciences, Genentech
Alex Lazar, PhD, Director, Analytical and Pharmaceutical Sciences, ImmunoGen, Inc.
Kelvin Lee, PhD, Professor, Chemical & Biomolecular Engineering, University of Delaware
Zhenhong Li, PhD, Senior Director, Analytics, RegenxBio
Anthony Mire-Sluis, PhD, Head, Global Quality, AstraZeneca
Jennifer F. Nemeth, PhD, SCPM, Director, Biophysics, Structural Characterization, Biologics Discovery Sciences, Janssen Research & Development
Da Ren, PhD, Principal Scientist, Amgen
Rich Rogers, PhD, Scientist, Just Biotherapeutics
Krishnan Sampath, PhD, Senior Director, Analytical and Drug Product Sciences, MacroGenics
Zhe Zhang, PhD, Senior Scientist, Integrated Biologics Profiling, Novartis

BIOPHYSICAL ANALYSIS OF BIOTHERAPEUTICS

George Bou-Assaf, PhD, Scientist, Technical Development, Biogen
Michael Brenowitz, PhD, Professor, Biochemistry and Molecular Pharmacology, Albert Einstein College of Medicine
Ralf Joe Carrillo, PhD, Senior Scientist, Physical Chemistry, AbbVie Bioresearch Center
John Champagne, Northeast Regional Manager, Wyatt Technology
Guodong Chen, PhD, Research Fellow, Bioanalytical and Discovery Analytical Sciences, Bristol-Myers Squibb
Mark T. Fisher, PhD, Professor, Biochemistry and Molecular Biology, University of Kansas Medical Center
Robert Hart, CEO, Halo Labs
David Hayes, PhD, Principal Scientist, Boehringer Ingelheim Pharmaceuticals, Inc.
Igor Kaltashov, PhD, Associate Professor, Chemistry, University of Massachusetts, Amherst
Hubert Kettenberger, PhD, Senior Principal Scientist, Protein Engineering, Roche Innovation Center Munich, Germany
Jennifer F. Nemeth, PhD, SCPM, Director, Biophysics, Structural Characterization, Biologics Discovery Sciences, Janssen Research & Development
Mark Pollo, Principal Scientist, Pfizer, Inc.
Deniz B. Temel, PhD, Scientist, Bristol-Myers Squibb
Nels Thorsteinson, Scientific Services Manager, Biologics, Chemical Computing Group
Kristopher Truncali, Scientist, Biophysics, Structural Characterization, Biologics Discovery Sciences, Janssen Research & Development
William Weiss, PhD, Principal Research Scientist and Group Leader, Biophysical Characterization, Eli Lilly and Company

PROTEIN AGGREGATION AND STABILITY IN BIOPHARMACEUTICALS

Andrea Allmendinger, PhD, Senior Scientist, Late-Stage Pharmaceutical and Processing Development, Biologics, F.Hoffmann-La Roche, Switzerland
Arun Alphonse Ignatius, PhD, Principal Scientist, Pfizer
David Brockwell, PhD, Associate Professor, School of Molecular and Cellular Biology, University of Leeds, United Kingdom
Didier Clenet, PhD, Research Scientist, Formulation & Stability, Sanofi Pasteur, Canada
Tom Crowley, PhD, Principal Scientist, Pharmaceutical R&D, Pfizer, Inc.
Zhimei Du, PhD, Head, Cell Line Development, Merck & Company, Inc.
Jason Fernandez, Scientist, Protein Pharmaceutical Development, Biogen
Raja Ghosh, PhD, Professor, Chemical Engineering, McMaster University, Canada
Zhi (Jay) Guo, PhD, Senior Scientist, Global Protein Sciences, AbbVie Bioresearch Center
Theodore W. Randolph, PhD, Professor, Chemical & Biological Engineering, University of Colorado, Boulder
John Rech, Technology Manager, Particle Testing, Analytical Laboratory, West Pharmaceutical Services
Peter Schurtenberger, PhD, Professor, Physical Chemistry, Lund University, Sweden
Peter M. Tessier, PhD, Professor, Pharmaceutical Sciences and Chemical Engineering, University of Michigan
Neal Whitaker, PhD, Associate Researcher, Macromolecule and Vaccine Stabilization Center, Pharmaceutical Chemistry, The University of Kansas School of Pharmacy
Yingda Xu, PhD, Director, Protein Analytics, Adimab

Immunogenicity & Bioassays Stream
IMMUNOGENICITY CASE STUDIES AND CLINICAL MANAGEMENT

Steven Arkin, MD, Executive Director, Clinical Programs, Rare Disease Research Unit, Pfizer Worldwide R&D
Adam Cheifetz, MD, Director, Center for Inflammatory Bowel Disease, Beth Israel Deaconess Medical Center; Associate Professor of Medicine, Harvard Medical School
Jocelyne Demengeot, PhD, Principal Investigator, Instituto Gulbenkian de Ciencia, Portugal
Sandra Garces, MD, PhD, Senior Medical Advisor for Immunogenicity, GPS Medical and Benefit-Risk Management, Eli Lilly and Company
Ann Gils, PhD, Professor, Pharmaceutical and Pharmacological Sciences, KU Leuven, Belgium
George R. Gunn, III, PhD, Head, Immunogenicity and Clinical Immunology, Bioanalysis, Immunogenicity and Biomarkers, In Vitro/In Vivo Translation Platform, GlaxoSmithKline
Soumi Gupta, PhD, Director of Immunogenicity, Translational Sciences, BioMarin Pharmaceutical, Inc.
Katherine A. High, MD, Co-Founder, President and Head of R&D, Spark Therapeutics
M. Benjamin Hock, PhD, Director of Immunogenicity, BioMarin Pharmaceutical Inc.
Darshana Jani, Senior Manager, Global Assay Lead, Drug Development, Pfizer
Vibha Jawa, PhD, Director, Immunogenicity Strategy for Biologics and Vaccines, Pharmacokinetics, Pharmacodynamics & Drug Metabolism, Merck & Co., Inc.
Priya Kishnani, MD, C.L. and Sue Chen Professor of Pediatrics, Division Chief, Medical Genetics, Duke University Medical Center
Chiyomi Kubo, PhD, DVM, Scientist, Research Division, Chugai Pharmaceutical Co., Ltd.
Kun Lu, PhD, Staff Scientist, Protein Biochemistry Group, Regeneron Pharmaceuticals, Inc.
Theo Rispens, PhD, PI Antibody Structure and Function, Sanquin
Amy S. Rosenberg, MD, Division Director, Office of Biotechnology Products, FDA/CDER
Jennifer Sims, Non-Clinical Expert, NDA Advisory Board, NDA Group
Karen Thudium, PhD, Head, Clinical Pharmacology Program, Cell and Gene Business Unit, Novartis

IMMUNOGENICITY ASSESSMENT AND REGULATORY APPROVAL OF BIOLOGICS

Tudor Arvinte, PhD, Professor, Biopharmaceutics, School of Pharmacy Geneva-Lausanne, University of Geneva and Therapeomic, Inc.
Björn Boll, PhD, Head, Particle Lab and Higher Order Structure Protein Analytics, Physical Chemical Analytics, Novartis Pharma AG
Steven Bowen, PhD, Immunogenicity Reviewer, OBP/OPQ/CDER, FDA
Shan Chung, PhD, Principal Scientist and Group Leader, Genentech, Inc.
Julio Delgado, MD, MS, CMO, ARUP Laboratories; Division Chief, Clinical Pathology, University of Utah School of Medicine; Associate Professor, Pathology, University of Utah
Jeremy Fry, DPhil, Director, Sales, ProImmune
William Hallett, PhD, Product Quality & Immunogenicity Reviewer, CDER/OPQ/OBP, FDA
Marisa K. Joubert, PhD, Principal Scientist, Process Development, Amgen, Inc.
Lynn Kamen, PhD, Scientist, BioAnalytical Sciences, Genentech
Uma Kavita, PhD, Senior Research Investigator, Analytical and Bioanalytical Operations, Bristol-Myers Squibb
Bernard Maillere, PhD, Director, Research and Head of Immunochemistry Laboratory, Institute Frederic Joliot, SIMOPRO, CEA, University Paris-Saclay
Shraddha Rane, PhD, Postdoctoral Research Associate, Infection Immunity and Respiratory Diseases, The University of Manchester
Susan Richards, PhD, Presidential Scientific Fellow, Translational Medicine Early Development, Sanofi R&D
Theo Rispens, PhD, Immunopathology, Sanquin Research, Amsterdam, Netherlands
Zuben E. Sauna, PhD, Research Biologist & Principal Investigator, Haemostasis Branch, Plasma Protein Therapeutics, Office of Tissues and Advanced Therapies, FDA/CBER
Noel Smith, PhD, Principal Group Leader, Applied Protein Services, Lonza Biologics
Daniela Verthelyi, PhD, Chief, Laboratory of Immunology, Office of Biotechnology Products, Office of Pharmaceutical Quality, CDER
Zhandong Don Zhong, PhD, Associate Director, Teva Pharmaceuticals

OPTIMIZING BIOASSAYS FOR BIOLOGICS

Joseph Callahan, PhD, Technical Development Scientist, Genentech, Inc.
Shan Chung, PhD, Principal Scientist and Group Leader, Bioanalytical Sciences, Genenetech, Inc.
Gaël Debauve, PhD, Associate Director, Bioassay Development, Analytical Sciences for Biologics, UCB
Jenny Hu, Scientist, PKDM, Amgen, Inc.
Natalia Kozhemyakina, PhD, Head, Bioassay Laboratory, Analytical Development Department, BIOCAD
Emily Lowe, PhD, Senior Scientist, Analytical Sciences, Kite Pharma, a Gilead Company
Areti Manola, Senior Principal Biostatistician, Non-Clinical Statistics, Manufacturing, Toxicology and Applied Statistical Sciences, Janssen, Pharmaceutical Companies of Johnson and Johnson
Kenneth R. Miller, PhD, Principal Scientist, Global Technical Operations, Analytical, AstraZeneca
Ashley Mullan, Scientist, Development, Analytical Sciences, MedImmune
Sandra Prior, PhD, Senior Scientist, Biotherapeutics, National Institute for Biological Standards and Control (NIBSC)
Perceval Sondag, Senior Manager, Statistics, PharmaLex
Dirk Usener, PhD, Head, Analytical Development 2, Bioanalytics, Sanofi
Steven Walfish, Principal Scientific Liaison, USP
Adrienne Wildt, PhD, Senior Scientist, Bioanalytical Science, Immunogen

Bioconjugates Stream
FUSION PROTEIN THERAPEUTICS

Ruben Boado, PhD, Vice President, Research & Discovery, ArmaGen Technologies, Inc.
Mathieu Cinier, PhD, CSO, Affilogic
Madiha Derouazi, PhD, CEO, Amal Therapeutics
Rachael Easton, MD, PhD, Executive Director, Clinical Development, Immunocore LLC
Stephen D. Gillies, PhD, Founder & CEO, Provenance Biopharmaceuticals
Ravindra Kumar, PhD, Senior Vice President & CSO, Acceleron Pharma, Inc.
Curtis Lockshin, PhD, Chief Scientific Officer, Xenetic Biosciences, Inc.
Ekkehard Moessner, PhD, Group Leader and Scientist, Protein Engineering, Roche Innovation Center Zurich
Niranjana Nagarajan, PhD, Principal Scientist, Celgene-Delinia
Nicola Pozzi, PhD, Assistant Professor, Biochemistry and Molecular Biology, Saint Louis University
Oliver Siefert, PhD, Scientist, Institute of Cell Biology and Immunology, University of Stuttgart
Patrik Strömberg, PhD, MBA, Senior Director, Head, Biomedical Science & Portfolio Innovation, Swedish Orphan Biovitrum AB (SOBI)
Kenneth W. Walker, PhD, Director, Research, Therapeutic Discovery, Amgen, Inc.
Zhirui Wang, PhD, Assistant Professor, Surgery, Harvard Medical School; Senior Investigator/Head, Immunotoxin Laboratory, Center for Transplantation Sciences (CTS), Massachusetts General Hospital
Stefan Weigand, PhD, Global Head, Large Molecule Research, Roche Diagnostics GmbH
Sunny Zhou, PhD, Professor and Faculty Fellow, Chemistry and Barnett Institute, Northeastern University

ENGINEERING ANTIBODY-DRUG CONJUGATES

Roger Beerli, PhD, CSO, NBE-Therapeutics AG
Dennis Benjamin, PhD, Senior Vice President, Translational Research, Seattle Genetics
Ravi Chari, PhD, Vice President, Chemistry & Biochemistry, ImmunoGen, Inc.
Kurt Gehlsen, PhD, Vice President & CSO, Therapeutics, Research Corporation Technologies, Inc.
Yelena Kovtun, Associate Director, Pipeline R&D, ImmunoGen, Inc.
Chawita Netirojjanakul, PhD, Scientist, Therapeutic Discovery, Amgen
Andreas Pahl, PhD, CSO, Heidelberg Pharma
Obadiah J. Plante, PhD, Director, Research, Visterra, Inc.
David Rabuka, Global Head, Research & Development, Chemical Biology, Catalent Biologics, Catalent Pharma Solutions
Jan E. Schnitzer, MD, Director, Professor, Cellular & Molecular Biology, Proteogenomics Research Institute for Systems Medicine (PRISM)
Ginette Serrero, PhD, CEO, A&G Pharmaceutical, Inc.
Philipp R. Spycher, PhD, PSI Founder Fellow, Center for Radiopharmaceutical Sciences, Paul Scherrer Institut
Breanna S. Vollmar, PhD, Senior Scientific Researcher, Protein Chemistry, Genentech, Inc.
Alain Wagner, PhD, Research Director, Biofunctional Chemistry, Faculty of Pharmacy, University of Strasbourg
Robert Yongxin Zhao, PhD, CEO, Hangzhou DAC Biotech Co., Ltd.

CLINICAL PROGRESS OF ANTIBODY-DRUG CONJUGATES

Adnan Abu-Yousif, PhD, Senior Scientist II, Discovery, Takeda
Donald A. Bergstrom, MD, PhD, CMO, Mersana Therapeutics
Anna Berkenblit, MD, MMSc, Vice President, CMO, ImmunoGen
Mahendra Deonarain, PhD, CEO & CSO, Antikor Biopharma Ltd.
David Goldenberg, ScD, MD, Founder and Former CSO, Immunomedics, Inc.
Trevor J. Hallam, PhD, CSO, Sutro Biopharma
Jay Harper, PhD, Senior Scientist, Oncology Research, MedImmune
Philip Howard, PhD, CSO, Spirogen; Senior Fellow, MedImmune
Gail Lewis Phillips, MSc, Senior Scientist, Translational Oncology, Genentech, Inc.
David (Shih-Yao) Lin, MD, PhD, CMO, AbGenomics, Inc.
Ed Reilly, PhD, Senior Research Fellow, Project Director, Oncology Discovery, AbbVie
Renu Singh Dhanikula, PhD, Senior Research Investigator, MAP, Bristol-Myers Squibb Company
Pamela Trail, Independent Consultant and Former Vice President, Oncology, Regeneron
Alessandra Micaela Villa, PhD, Head, Phage Display Technologies, Philochem AG
Jeff Wallin, PhD, Senior Director and Head, Biomarkers & Diagnostics, Seattle Genetics
William C. Zamboni, PharmD, PhD, Associate Professor and Director, Translational Oncology and Nanoparticle Drug Development Initiative (TOND2I) Laboratory, UNC Lineberger Comprehensive Cancer Center

Therapeutics & Technologies Stream
EMERGING INDICATIONS FOR THERAPEUTIC ANTIBODIES

Dan Allison, PhD, Senior Director, Antibody Technologies, Alder Biopharmaceuticals
Robin Barbour, Head, Antibody and Assay Development, Research, Prothena Biosciences
Gabriela Dos Santos Cruz De Matos, PhD, Senior Scientific Investigator, Biopharm Molecular Discovery, GlaxoSmithKline, United Kingdom
Joachim Feldwisch, PhD, Director, Preclinical Development, Affibody AB, Sweden
Robert P. Giugliano, MD, Senior Investigator, TIMI Study Group, Staff Physician, Cardiovascular Medicine, Brigham and Women’s Hospital; Associate Professor, Medicine, Harvard Medical School
Gregory C. Ippolito, PhD, Research Assistant Professor, Molecular Biosciences, Georgiou Lab, The University of Texas at Austin
Leonard Kaczmarek, PhD, Professor, Pharmacology, Cellular and Molecular Physiology, Yale University School of Medicine
Hikaru Koga, Researcher, Biologics Discovery Department, Chugai Pharmaceutical Co., Ltd., Japan
Thomas Mikita, PhD, Director, Centers for Therapeutic Innovation, Pfizer, Inc.
Janice M. Reichert, PhD, Executive Director, The Antibody Society
Luke Robinson, PhD, Associate Director, Research, Visterra, Inc.
Dan Sexton, PhD, Director, Pharmacology, Shire
Devin Sok, PhD, Director, Antibody Discovery and Development, International AIDS Vaccine Initiative (IAVI)
Christine Tkaczyk, PhD, Senior Scientist, Infectious Diseases/Vaccines, MedImmune
Tianlei Ying, PhD, Head, Antibody Engineering and Drug Discovery Group, School of Basic Medical Science, Fudan University, China
Ali Zarrin, PhD, Senior Scientist, Immunology and Antibody Engineering, Genentech

CRISPR FOR GENOME ENGINEERING

Aaron T. Cheng, PhD, Head, PTS Discovery Genome Editing, Protein Cellular and Structural Sciences, R&D Platform Technology & Science, GlaxoSmithKline
John McCafferty, PhD, CEO, Antibody Engineering, IONTAS, Ltd.
Patrick Collins, PhD, Senior Scientist, Genome Analysis Unit, Amgen
Marina Falaleeva, PhD, Scientist I, Development, Sangamo Therapeutics
John Feder, PhD, Associate Director, Genome Biology, Bristol-Myers Squibb
Gus Frangou, PhD, Fellow, Molecular and Integrative Physiological Sciences, Harvard TH Chan School of Public Health
Tony Ho, MD, Executive Vice President, Head of R&D, CRISPR Therapeutics
Fuguo Jiang, PhD, Postdoc Fellow, Molecular and Cell Biology, University of California, Berkeley
Colin A. Johnson, PhD, Professor of Medical & Molecular Genetics, Section of Ophthalmology and Neurosciences, Leeds Institute of Molecular Medicine
Julia Joung, Graduate Student. Biological Engineering, MIT
Kristian Laursen, PhD, Professor, Pharmacology, Cornell University
Chengzu Long, PhD, Asst Professor, Department of Medicine, New York University
Bettie Osuna, PhD, Graduate Student, Bondy-Denomy Lab, University of California, San Francisco

NANOTECHNOLGY IN MEDICINE

Itai Benhar, PhD, Professor, Molecular Microbiology and Biotechnology, The George S. Wise Faculty of Life Sciences, Tel Aviv University
Michelle Bradbury, MD, PhD, Director, Intraoperative Imaging, Radiology, Memorial Sloan Kettering Cancer Center
Jose Luis Corchero Nieto, PhD, Senior Scientist, Nanobiotechnology Group, CIBER-BBN, Institute of Biotechnology and Biomedicine, Universitat Autonoma de Barcelona
Brian T. Cunningham, PhD, Willett Professor of Engineering, Director, Micro and Nanotech Lab, Electrical and Computer Engineering, University of Illinois at Urbana -Champaign
Daryl Drummond, PhD, Head of Research, Merrimack Pharmaceuticals
Ali Fattom, PhD, Senior Vice President, Vaccine R&D, NanoBio Corp.
Seungpyo Hong, PhD, Professor, Pharmaceutics, Pharmaceutical Sciences Division, School of Pharmacy, University of Wisconsin-Madison
Taeghwan Hyeon, PhD, SNU Distinguished Professor, School of Chemical and Biological Engineering, Seoul National University
Kei Kishimoto, PhD, CSO, Selecta Biosciences
Paul Millner, PhD, Professor of Bionanotechnology, School of Biomedical Sciences, University of Leeds
Hayat Onyuksel, PhD, Professor, Biopharmaceutical Sciences, University of Illinois
Jianghong Rao, PhD, Professor, Radiology and Chemistry (courtesy), Molecular Imaging Program, Cancer Biology and Biophysics Programs, Stanford University
Jan E. Schnitzer, MD, Director, Professor of Cellular & Molecular Biology, Proteogenomics Research Institute for Systems Medicine (PRISM)
Jinjun Shi, PhD, Assistant Professor, Center for Nanomedicine, Brigham and Women’s Hospital, Harvard Medical School
Matthias Stephan, MD, PhD, Associate Member, Fred Hutchinson Cancer Research Center, Associate Professor, University of Washington

TRAINING SEMINARS

David Bramhill, PhD, Founder, Bramhill Biological Consulting, LLC
Christopher Corbeil, PhD, Research Officer, Human Health Therapeutics, National Research Council Canada
Masha Fridkis-Hareli, MSc, PhD, Founder and President, ATR, LLC
Simon Friedensohn, MSc, Research Assistant; Biosystems Science and Engineering, ETH Zurich, Switzerland
Arno Kromminga, PhD, Member, European Immunogenicity Platform, Senior Vice President and European CSO, BioAgilytix
Sheila G. Magil, PhD, Senior Consultant, BioProcess Technology Consultants, Inc.
Enkelejda Miho, Ph.D., Research Assistant II, Biosystems Science and Engineering; Pioneer Innovation & Entrepreneurship Lab, ETH Zürich, Switzerland
Tatiana Novobrantseva, PhD, Co-Founder, Head of Research and Development, Verseau Therapeutics
Frank J. Riske, PhD, Senior Consultant, BioProcess Technology Consultants, Inc.
Perceval Sondag, Senior Manager, Statistics, PharmaLex
Traian Sulea, PhD, Senior Research Officer, Human Health Therapeutics, National Research Council Canada

SHORT COURSE INSTRUCTORS

Richard Altman, MS, Scientist, Protein Technologies, Amgen
Tara Arvedson, PhD, Director, Oncology Research, Amgen
Glareh Azadi, PhD, Senior Scientist, Translational PKPD, Merck Research Laboratories
Gadi Bornstein, PhD, Senior Director, Biologics Discovery, TESARO, Inc.
Christine P. Chan, PhD, Principal Scientist, Global Manufacturing Science & Technology, Sanofi
Henry C. Chiou, PhD, Associate Director, Cell Biology, Life Science Solutions, Thermo Fisher Scientific
Kelly Doering, PhD., DMPK Business Manager, Pharmaceutical Business, Waters
Soldano Ferrone, MD, PhD, Division of Surgical Oncology, Surgery, Massachusetts General Hospital, Harvard Medical School
Isabel Figueroa, PhD, Scientist, PTPK, Genentech, Inc.
Dennis Ford, Founder and CEO, Life Science Nation
Ben Hock, PhD, Director, Immunogenicity, BioMarin Pharmaceuticals
Darshana Jani, MS, Senior Manager, Pfizer, Inc.
Moonsoo M. Jin, PhD, Associate Professor, Molecular Imaging Innovations Institute, Radiology, Weill Cornell Medical College
Veronica Juan, PhD, Principal Scientist, Protein Sciences, Merck Research Labs
Scott L. Klakamp, PhD, Vice President of Chemistry and Biochemistry, Bioptix
Seema Kumar, PhD, Associate Director, Quantitative Pharmacology & Drug Disposition (QPD), R&D Global Early Development (GED), EMD Serono, a business of Merck KGaA, Darmstadt, Germany
Christian Kunz, PhD., Associate Director, MorphoSys AG
Vinodh B. Kurella, PhD, Senior Scientist, Protein Engineering, Immuno-Oncology Division, Intrexon Corp.
Paul Rhyne, PhD., VP, Biological Development Services
Jonas V. Schaefer, PhD, Lab Head/Investigator II, Novartis Institutes for BioMedical Research (NIBR)
Ravi Shankar Singh, PhD, Associate Director, Clinical Pharmacology, Pfizer
Mohammad Tabrizi, PhD, Director Biologics Discovery, Merck Research Laboratories Palo Alto
Magdalena Tary-Lehmann, MD, PhD, CSO, Cellular Technology Limited (CTL); Adjunct Associate Professor of Pathology, Case Western Reserve University (CWRU)
Bojiao Yin, PhD, Scientist, Protein Technologies, Amgen